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Abstract
Sickle Cell Disease (SCD) is a hereditary monogenic disorder that affects millions
of people worldwide and is associated with symptoms such as stroke, lethargy, chronic
anemia, and increased mortality. SCD can be quickly detected and diagnosed using a
simple blood test as an infant, but as of now, there is currently limited treatment to cure
an individual of sickle cell disease. Recently, there have been several promising
developments in CRISPR-Cas-associated gene-editing therapeutics; however, there have
been limitations in gene-editing efficiency monitoring, which if improved, could be
beneficial to advancing CRISPR-based therapy, especially in SCD. The CRISPR-Chip, a
three-terminal graphene-based field effect transistor (gFET), was used to detect genomic
samples of individuals with SCD, with and without amplification. With the dRNP-HTY3’
complex, CRISPR-Chip was able to specifically detect its target sequence with and
without pre-amplification. With the dRNP-MUT3’ complex, CRISPR-Chip was only able
to specifically detect one of its two target sequences. Facile detection, analysis, and
editing of sickle cell disease using CRISPR-based editing and monitoring would be
beneficial for simple diagnostic and gene-editing therapeutic treatment of other single
nucleotide polymorphisms as well, such as beta-thalassemia and cystic fibrosis.
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Introduction
Sickle Cell Disease (SCD) is a hereditary monogenic disorder that affects millions
of people worldwide and is associated with symptoms such as stroke, lethargy, chronic
anemia, and increased mortality (Bialk et al., 2016; Park et al., 2016). SCD includes all
genotypes with at least one sickle gene and is caused by a single nucleotide
polymorphism (SNP) in the β-globin gene (HBB) on chromosome 11, converting a GAG
codon to a GTG codon in exon 1 (Bialk et al., 2016; Park et al., 2016). SCD can be
quickly detected and diagnosed using a simple blood test as an infant; however, there is
currently limited treatment to cure an individual of sickle cell disease. As of now,
allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment
available. HSCT for SCD uses donor allogeneic stem cells from a family-related or an
unrelated donor, from the bone marrow, peripheral blood or cord blood (Galgano and
Hutt, 2018). These stem cells are then intravenously infused into patients with SCD. This
treatment is an invasive procedure associated with high risk of graft-versus-host-disease,
infections, and infertility, and is only feasible for approximately 15% of the patient
population due to lack of compatible human leukocyte antigen (HLA)-matched donors
(Kassim and Sharma, 2017; Park et al., 2016).
In recent years, researchers have utilized multiple techniques to improve upon
HSCT therapies in order to cure SCD. These techniques include viral vector-based donor
templates and gene-editing methods such as zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), and clustered regularly-interspaced Short
palindromic repeats (CRISPR)-associated nuclease (Cas) (Demirci et al., 2018; Gupta
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and Musunuru, 2014; Lux et al., 2019; Moran et al., 2018; Sebastiano et al., 2011; Sun
and Zhao, 2014; Tasan et al., 2016).
CRISPR-Cas9-based gene-editing technology
Compared to the other methods, CRISPR-Cas is inexpensive and demonstrates
higher ease of use and modifiability (Gupta and Musunuru, 2014; Tasan et al., 2016).
CRISPR-Cas9 uses a 20-nucleotide single-stranded guide RNA (sgRNA) sequence that is
complementary that is adjacent to a protospacer adjacent motif (PAM), usually NGG
(Anders et al., 2014; Aryal et al., 2018). CRISPR-Cas9’s modifiability comes from only
needing to change the 20-nucleotide sgRNA sequence to target any genomic sequence
(Gupta and Musunuru, 2014). However, Cas9 protein size and CRISPR-Cas9’s off-target
effects are the two main concerns regarding the CRISPR-Cas9 gene-editing method.
Compared to the other two popular gene-editing methods, ZFN and TALENS,
CRISPR-Cas9 is significantly larger in size, making it more difficult to deliver using viral
vectors or as an RNA molecule (Gupta and Musunuru, 2014).
While CRISPR-Cas9’s specificity and binding are attributed to its 20 nucleotide
protospacer and the PAM, there have been reports of off-target cleavage activity and
varying levels of on-target efficiency depending on the sgRNA sequence selected (Aryal
et al., 2018; Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013). However, since
these off-target effects usually stem from the sgRNA sequence, this issue can be
mitigated by choosing a sgRNA sequence with the least known off-target effects. It is
also important to note that many reports of high-frequency off-target activity have been
associated with human and mouse cell-lines, but there have been few reports of off-target
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effects in mammalian embryo editing (Hsu et al., 2013; Iyer et al., 2018; Nakajima et al.,
2016). One study done demonstrated CRISPR-Cas9’s efficiency of 80% in targeting both
alleles of two genes in mice, which indicates CRISPR-Cas9 as a promising tool in
gene-editing therapeutics (Wang et al., 2013).
Multiple studies have used CRISPR/Cas9 genome editing technology to correct
the sickle cell mutation in CD34+ hematopoietic stem and progenitor cells (HSPCs) and
have demonstrated relatively high editing efficiencies and clinically relevant gene-editing
rates (DeWitt et al., 2016; Hoban et al., 2016; Lin et al., 2017; Park et al., 2016; Tasan et
al., 2016). These results are indicative of the possible applications of CRISPR/Cas9 in
targeting the specific mutation in SCD. Using CD34+ HSPCs from patient with SCD, one
lab used CRISPR-Cas9 with a single-stranded DNA oligonucleotide donor (ssODN) to
achieve efficient correction of the SCD mutation in human HSPCs (DeWitt et al., 2016).
The edited HSPCs produced less sickle hemoglobin RNA and protein, as well as
demonstrated increased levels of wild-type hemoglobin upon differentiating into
erythroblasts. Immunocompromised mice were treated ex vivo with engraftment of the
human HSPCs, and the HSPCs maintained the SCD gene edits for sixteen weeks at levels
indicative of having clinical benefit.
Another study used both TALENs and CRISPR-Cas9 methods to target the sickle
cell mutation in HBB to evaluate on-target and off-target cleavage rates (Hoban et al.,
2016). To measure these gene modification rates through homology directed repair
(HDR), they co-delivered TALENs and CRISPR-Cas9 to K562 3.21 cells, which contain
the sickle mutation, with a homologous donor template containing the HBB gene. While
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TALENs demonstrated average gene modification rates between 8.2% - 26.6%,
CRISPR-Cas9 produced an overall higher rate of 4.2 - 64.3% and thus was chosen to
facilitate SCD correction in HSPCs. CRISPR-Cas9 delivery to HSPCs demonstrated in
vitro gene modification rates in HSPCs at over 18%. To test CRISPR-Cas9’s clinical
applications, the lab corrected the SCD mutation in bone-marrow derived CD34+ HSPCs
from patients with SCD, which resulted in wild-type hemoglobin production, further
supporting CRISPR-Cas9’s use as gene-editing tool for patient with SCD. Current
methods of ex vivo CRISPR/Cas9-based gene-editing techniques have only been tested in
vitro human cell cultures or in vivo mouse models, and there are currently no research
trials involving humans directly (DeWitt et al., 2016; Hoban et al., 2016). However,
clinical trials are on the horizon, meaning CRISPR-Cas9 ex vivo editing of
SCD-associated mutations will need to be constantly monitored before any potential
reintroduction into patients.
Besides genome editing, gene therapy monitoring and diagnostics are emerging
applications in the CRISPR-Cas systems (Mintz et al., 2018; Uppada et al., 2018). In a
recent study, researchers developed a new technology with sensitivity and specificity in
detecting unamplified target DNA sequences with the insertion of the bfp (blue
fluorescent protein) gene and large fragment deletions relevant in Duchenne muscular
dystrophy clinical samples (Hajian et al., 2019). This new technology termed
CRISPR-Chip, a graphene-based field effect transistor with CRISPR/dCas9 immobilized
on the surface, has potential to play a part in the development of CRISPR-based therapy
as a gene-editing monitoring tool.
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Conventional nucleic acid-based detection methods require amplification of the
target genome sequences, such as PCR, in order to validate the presence of a target gene
(Cao et al., 2017; Hudecova, 2015). In addition, many nucleic acid detection technologies
are expensive, require multi-step processes as well as bulky, complex instruments, which
are time-consuming and require trained personnel for operation. CRISPR-Chip
overcomes these limitations as it is a hand-held, label-free device that is affordable, easy
to use, and only requires a short amount of time for target gene detection.

CRISPR-Chip background information
CRISPR-Chip is comprised of two main parts: its graphene-based field effect
transistor (gFET) platform and an immobilized CRISPR-nuclease dead cas9 (dcas9)
protein complex. This graphene substrate was chosen as it is known for its excellent
electrical conductivity, large surface area, and high sensitivity to the adsorption and
interactions of charged molecules (Peña-Bahamonde et al., 2018; Pumera, 2011). The
CRISPR-Chip is a CRISPR-enhanced, three-terminal gFET, with source, drain, and
liquid-gate electrodes as shown in Figure 1 (Hajian et al., 2019).
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Figure 1. CRISPR-Chip graphic: the CRISPR-Chip, a graphene field effect transistor,
with immobilized dCas9 and sgRNA is able to detect its target sequence. Reproduced
from “Detection of unamplified target genes via CRISPR–Cas9 immobilized on a
graphene field-effect transistor,” by R. Hajian et al., 2019, Nature Biomedical
Engineering. Copyright 2019 by Springer Nature. Reprinted with permission.

The immobilized dead cas9 protein complex contains a 20-nucleotide
single-stranded guide-RNA (sgRNA) molecule bound as a ligand. This complex is
termed as dRNPs (dead cas9- ribonucleoproteins) hereafter. The sgRNA can be easily
designed to complement a specific target sequence. The designs of the sgRNAs used in
this study will be discussed in the Materials and Methods section (pg. 14). The dRNP,
similar to CRISPR-Cas9 activity, will probe the entire genomic sample until it finds its
target sequence; however, since the NUC lobe of the dcas9 is catalytically inactive,
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instead of cleaving its target sequence, the dRNP will unzip the double helix and the
sgRNA will bind upstream of the protospacer adjacent motif (PAM) (Boyle et al., 2017;
Jiang and Doudna, 2017).
The biosensor is functionalized with dRNP immobilization onto the graphene chip
via a molecular linker, 1-pyrenebutanoic acid (PBA). First, PBA non-covalently binds
with the graphene surface through π–π aromatic stacking interactions, followed by
covalent binding of PBA’s carboxylate group to the dCas9 protein, tethering the protein
onto the CRISPR-Chip. As shown in Fig 2, any PBA molecules that do not have any
attached dCas9 will be blocked by amino-polyethylene glycol 5-alcohol (PEG); however,
what is not shown in the figure, subsequent addition of ethanolamine hydrochloride.
These blocking molecules (known in the protocol as Quench 1 and Quench 2) are
important as they hinder any non-specific adsorption or binding of charged molecules
onto the graphene surface. After immobilizing dCas9 onto and saturating the graphene
platform, sgRNA is added onto the chip to conjugate with the dCas9 to create the dRNP
complex. More information on the protocol can be found in the Materials and Methods
section (pg. 17-19).
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Figure 2. Schematic of CRISPR-Chip functionalization. Adapted from “Detection of
unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect
transistor,” by R. Hajian et al., 2019, Nature Biomedical Engineering. Copyright 2019 by
Springer Nature. Reprinted with permission.

The CRISPR-Chip is inserted to a hand-held reader that is connected to a
computer program which displays the response. The functionalization of the graphene
surface acts as a channel between the source and drain electrodes, with the third terminal
being a liquid gate that interacts with the genomic sample which is contained in a
reaction buffer. Voltage is applied across the surface between the liquid-gate and source
electrodes (Vg). Due to graphene’s sensitivity to interactions with charged molecules on
its surface, binding of the negatively-charged target DNA to the RNP will modify the
conductivity of graphene, and this binding will be read by the CRISPR-Chip reader as an
electrical current. Binding of the target DNA with the dRNP will result in a larger
electrical output signal from the reader while minimal binding of non-target DNA with
the dRNP will result in a significantly smaller electrical response. For more detailed
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description of the CRISPR-Chip operational and measurement methods, please refer to
the Hajian 2019 paper.
Earlier this year, the CRISPR-Chip successfully analyzed DNA samples collected
from HEK293T cell lines that expressed bfp and clinical samples of DNA of patients with
Duchenne muscular dystrophy (DMD) (Hajian et al., 2019). They were able to detect and
differentiate genomic samples of DNA with and without bfp or DMD. The lab tested two
different clinical samples of DMD: one containing deletion of exon 3 and the other
containing deletion of exon 51. They used clinical samples of healthy patients as a
control. The CRISPR-Chip detection of DMD is a break-through technology as it can be
used as an inexpensive and facile diagnostic tool in a clinical setting. In addition, the
ability of the CRISPR-Chip to detect target sequences in a genomic sample without
amplification of the target sequence demonstrates its sensitivity and specificity.

Single nucleotide polymorphisms
A single nucleotide polymorphism (SNP) is a single nucleotide base mutation, in
which one of the bases (A, T, C, G) are replaced with another base. Sickle cell disease is
caused by a SNP, and while it is one of the diseases that can be easily diagnosed by a
simple blood test, detecting SNPs in general has proven difficult. Current methods of
detecting SNPs require complex processes and amplification of the target sequence in
order to achieve detection and have poor specificity and sensitivity (Ficht et al., 2004;
Gerion et al., 2003; Xiao et al., 2009). Recently, there has been more development in
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using electrical biosensors, which have lowered the limit of detection of target DNA to
the femtomolar level (Lu et al., 2014; Ping et al., 2016).

Objective
In this study, I hypothesize that we will be be able to use the CRISPR-Chip
platform to detect the sickle cell disease-associated SNP without amplification.
Compared to the indels from the bfp gene and from the mutations in DMD, the sickle cell
associated-SNP may be more difficult to detect from unamplified genomic samples as the
SCD target sequence only has one base pair difference to a healthy genomic sequence, as
well as due to the promiscuity of the CRISPR-Cas system (Tsai et al., 2017). If a sgRNA
has high off-target activity, this may inhibit our ability to detect a single mismatch in the
dRNP target sequence. As the CRISPR-Cas9 gene-editing technology is already known
for its off-target effects, this may be a challenge for using the CRISPR-Chip to detect a
SNP. However, successes of SCD correction in HSPCs using CRISPR-Cas9 shown in
previous literature, as well as the sensitivity and specificity of the CRISPR-Chip, are
promising in optimizing the CRISPR-chip device in detecting the SCD-associated SNP
(DeWitt et al., 2016; Hajian et al., 2019; Hoban et al., 2016).
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Materials and Methods
Single guide RNA (sgRNA) design
For sickle cell disease (SCD) analysis via CRISPR-Chip, 3 sgRNAs were
designed utilizing multiple sgRNA designing programs and a sgRNA used in previous
literature (Bialk et al., 2016). The HBB gene was input into these programs, and the
sgRNA sequences chosen targeted sequences in exon 1 where the single point mutation
causing SCD was located. The first sgRNA sequence, termed sgRNA MUT 3’, targeted a
sequence with the SCD mutation: 5’ GTAACGGCAGACTTCTCCAC 3’. The sgRNA
was named sgRNA MUT3’ because the SCD mutation is the second base pair from the 3’
end. sgRNA MUT3’ was designed based off of online sgRNA design programs: GUIDES
Designer, Chop Chop, CRISPOR, and Synthego. The second sgRNA sequence, termed
sgRNA MUT 5’, targeted a different sequence with the same SCD mutation: 5'
CTCAGGAGTCAGATGCACCA 3'. sgRNA MUT5’ was termed this name because the
SCD mutation is the second base pair from the 5’ end. sgRNA MUT5’ was designed
based off of online sgRNA design programs: DNA 2.0, CRISPOR, and Synthego. The
third sgRNA sequence, termed sgRNA HTY 3’, targeted the same sequence as sgRNA
MUT3’ without the SCD mutation: 5’ GTAACGGCAGACTTCTCCTC 3’. sgRNA
HTY3’ was generated by online sgRNA design programs: GUIDES Designer, Chop
Chop, CRISPOR, and Synthego. In addition, sgRNA HTY3’ has also been successfully
used to cleave the target sequence in previous literature (Bialk et al., 2016).
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sgRNA selection and design schematic
Target sequence:

5’ GTAACGGCAGACTTCTCCTC 3’

Sickle cell mutation:

5’ GTAACGGCAGACTTCTCCAC 3’

sgRNA sequence:

5’ GUAACGGCAGACUUCUCCAC 3’

sgRNA sequences (5’ to 3’)
sgRNA MUT 3’: GUAACGGCAGACUUCUCCAC
sgRNA HTY 3’: GUAACGGCAGACUUCUCCUC
sgRNA MUT 5’: CACAGGAGUCAGAUGCACCA

Primer selection
For validation of the designed sgRNAs, primers were designed using Thermo
Fisher Scientific’s Primer Design Tool. The HBB gene was inputted into the program,
and 3 paired primers that encompassed the entirety of exon 1 were produced. All 3 paired
primers were guaranteed to have a 95% success rate in sequencing viability, and the
longest amplicon length (506 base pairs) was chosen as caution to capture the entire exon
1 and for better visibility during PCR. The forward and reverse primer sequences were
TTGAGGTTGTCCAGGTGAGCCA and GGCCAATCTACTCCCAGGAGCA
respectively.
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Genomic DNA sample selection
Human genomic samples from two male patients affected by sickle cell disease
were purchased with certificate of analysis from Coriell Institute for Medical Research
(Camden, NJ). Sample SCD1 (NA16265) is a sample from a 19-year old African
American male with homozygous sickle cell diseases (HbSS). Sample SCD2 (NA16267)
is a sample from a 3-year old African American male with two copies of the sickle cell
mutation. The concentrations were routinely measured prior to incubation with
CRISPR-Chip using Infinite M200 Nanoquant (Tecan).

PCR protocol
HBB e xon 1 was amplified from 100ng genomic DNA via PCR according to
manufacturer's protocols. In a 50µL reaction mixture, the following reagents were used:
100ng genomic DNA (NA16265, NA16267), 10 µL 5X Phusion HF Buffer, 1 µL dNTP,
5 µL forward primer, 5 µL reverse primer, 0.5 µL Phusion DNA polymerase and, X µL
H2O (X denotes the remaining solution needed to create a 50µL mixture). The following
PCR thermal cycler protocol was used (PTC-100: Programmable Thermal Controller, MJ
Research Inc., U.S.): (1) 98˚C for 30 sec (2) 98˚C for 10 sec (3) 63.5˚C for 30 sec (4)
72˚C for 15 sec (5) repeat 2-4 29x (6) holding at 72˚C for 5 min prior to cooling to 4˚C.
The forward and reverse primer sequences were TTGAGGTTGTCCAGGTGAGCCA
and GGCCAATCTACTCCCAGGAGCA respectively. 2 µL of the PCR products were
loaded on a 1% agarose gel 100V for 1hr, followed by an ethidium bromide bath
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(0.5µg/ml, 30min). Once stained, the gel was imaged using the UVP ChemStudio
(Analytikjena, Germany)

CRISPR-Chip Molecular Linker Functionalization and Activation
Naked graphene FET chips were obtained (Cardea, San Diego CA) and cleaned
with 30µL acetone twice and 30µL deionized water (DIW) once. The chips were
subsequently functionalized with 1-pyrenebutanoic acid (PBA) (5mM, 15 µl) in
dimethylformamide (DMF) for 2 hours at room temperature or overnight at 4˚C.
Following the incubation, the graphene sensor was rinsed with 30µL DMF twice and
30µL DIW once. The PBA was activated using a 1:1 volume ratio of
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 4mM) and
N-hydroxysuccinimide (NHS, 11mM) (Sigma Aldrich) in 50 mM of 2-(N-Morpholino)
ethanesulfonic acid (MES, pH 6) for 5 minutes at room temperature according to
published literatures prior to incubation with dCas9 (Everaerts et al., 2008; Wang et al.,
2011).

CRISPR–Chip evaluation for the detection of SCD in the presence of Amplicons
The dRNP-HTY3’ and dRNP-MUT3’ functionalized CRISPR-Chips were
calibrated with 2mM MgCl2 for 5min at 37 °C and subsequently incubated with 900ng of
amplicons SCD1 or SCD2 (30 µl in 2mM MgCl2) for 25min at 37 °C. For the control
experiments, amplicons of healthy DNA without the SCD mutation or amplicons without
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the HBB sequence were incubated with dRNP-HTY3’- and dRNP-MUT3’-functionalized
CRISPR–Chips. For all experiments, the sensor was rinsed (2mM MgCl2, 30 µl) for
15min at 37 °C after incubation with the genomic sample.

CRISPR–Chip detection of SCD in the presence of Genomic DNA
The dRNP-HTY3’-functionalized CRISPR–Chips were calibrated with 2mM
MgCl2 for 5min at 37 °C and subsequently incubated with 1800ng SCD1 or SCD2 DNA
(30µl in 2mM MgCl2). For the control experiments, 1800ng of healthy human embryonic
kidney (HEK) DNA was incubated with dRNP-HTY3’-functionalized CRISPR-Chips.
For all experiments, the CRISPR–Chip response was continuously monitored for
25 minutes at 37 °C. CRISPR–Chips were then rinsed (2mM MgCl2, 30 µl) for 15
minutes at 37 °C after incubation with the genomic sample. 1800ng genomic DNA was
used instead of 900ng because initial tests of 900ng genomic DNA samples were too low.

CRISPR-Chip Complete Assay Protocol
1. Calibration of PBA-functionalized chips with 50mM MES for 5 minutes.
2. Activate the PBA linker with a mixture of 4mM EDC and 11mM NHS for 5
minutes.
3. Rinse any unbound PBA linker with 50mM MES (2x) for 1 minute.
4. Association of the PBA linker with 900ng (30 µl in 2 mM MgCl2) dCas9 for 15
minutes.
5. Association of Quench 1 containing 1mM amino-PEG5-alcohol for 10 minutes.
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6. Association of Quench 2 containing 1M ethanolamine hydrochloride for 10
minutes.
7. Rinse any unbound Quench 1 and Quench 2 with 2mM MgCl2 (5x) for 1 minute.
8. Calibration for sgRNA with 2mM MgCl2 for 5 minutes.
9. Association of 900ng (30 µl in 2 mM MgCl2) sgRNA for 10 minutes.
10. Rinse away any unbound sgRNA and calibrate for DNA with 2mM MgCl2 for
5

minutes.
11. Association of Xng (30 µl in 2 mM MgCl2) DNA for 25 minutes. (X= 900ng or
1800ng, depending on the type of sample used).
12. Rinse of any unbound DNA with 2mM MgCl2 for 15 minutes.

CRISPR-Chip Sensor Response, Measurement, and Analysis Methods
The sensor response was recorded in real-time as shown in Figure 3, and the data
were analyzed using equation below, which was used in previous literature (Hajian et al.,
2019). Each chip consists of three transistors that separately measure the current, and
these individual transistor responses can be analyzed separately. Ids is the signal after
incubation with the DNA sample and subsequent rinsing. Ids0 is the calibration baseline
signal after the assay buffer was incubated during calibration. The calibration step takes
into account sensor-to-sensor variation and effects of the buffer. I-response (%) the unit
of measure, is the percentage change in between Ids0 (calibration baseline) and Ids (the
response after rinsing of the target DNA).
I-response (%) =

100(Ids−Ids0)
Ids0
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Figure 3. Real-time CRISPR-Chip I-Response (%), average current, is monitored
throughout sensor functionalization and analysis with dRNP-HTY3’. The yellow line
indicates the I-Response (%) of dRNP-HTY3’-Healthy Genomic DNA and the blue line
indicates the I-Response (%) of dRNP-HTY3’-SCD1 Genomic DNA. The white regions
represent rinsing and calibration with 2mM MgCl2.

Results
Selectivity of the immobilized dRNP-HTY3’ with amplicon sequences
CRISPR-Chip’s detection of the SCD mutation was first tested using amplicon
sequences of two different DNA samples containing the SCD mutation. The first control
was amplicon sequences from healthy DNA without the SCD mutation, and the second
control (Scram) was amplicon sequences that did not include the HBB gene sequence.
The PCR protocol for DNA amplification can be found in the Methods section. Each
combination of dRNP-HTY3’ with (900ng Amplicon) was ran at least three times.
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I found evidence to support selective binding and detection of dRNP-HTY3’ for
Healthy amplicon. The average responses of the four amplicon samples (Healthy, SCD1,
SCD2, and Scram) were different, with Healthy amplicon with the highest average
response at 10.04 and Scram amplicon with the lowest response at 5.67 (One-Way
ANOVA: F3, 39 =
 8.044, p = 0.000272, Fig. 4). A post-Tukey test was performed and
further supports dRNP-HTY3’ complex’s higher affinity of binding with Healthy
amplicon. The results are shown in the Table 1 (* notes statistical significance).

Figure 4. The relationship between dRNP-HTY3’ (900ng amplicon type) and average
I-Response (%). Bar heights and bars represent means ± standard deviation. Healthy
(n=10), SCD1 (n=15), SCD2 (n=9), Scram (n=9) (n= number of working transistors).
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Table 1. Post-Tukey analysis of dRNP-HTY3’ sensor responses of amplicon samples
Amplicon Comparison

P-adjusted value

Healthy-SCD1 *

0.0042601

Healthy-SCD2 *

0.0251331

Healthy-Scram *

0.0001736

SCD1-SCD2

0.9917302

SCD1-Scram

0.3807639

SCD2-Scram

0.3361175

Specificity of the immobilized dRNP-HTY3’ with genomic sequences
Genomic DNA samples of Healthy DNA extracted from HEK cells and the two
different DNA samples containing the SCD mutation were tested with the dRNP-HTY3’
complex.  Each combination of dRNP-HTY3’ with (1800ng Genomic Sample) was ran at
least two times.
I found evidence to support selective binding and detection of dRNP-HTY3’ for
Healthy amplicon. The average responses of the three genomic samples (Healthy, SCD1,
and SCD2) were different, with Healthy genomic sample with the highest average
response at 4.48 and SCD1 genomic sample with the lowest response at 0.57 (One-Way
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ANOVA: F2, 24 =
 58.87, p = 5.55e-10, Fig. 5). A post-Tukey test was performed and
further supports dRNP-HTY3’ complex’s higher affinity of binding with Healthy
genomic sample. The results are shown in the Table 2 (* notes statistical significance).

Figure 5. The relationship between dRNP-HTY3’ (1800ng genomic type) and average
I-Response (%). Bar heights and bars represent means ± standard deviation. Healthy
(n=6), SCD1 (n=12), SCD2 (n=9) (n= number of working transistors).
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Table 2. Post-Tukey analysis of dRNP-HTY3’ sensor responses of genomic samples
Amplicon Comparison

P-adjusted value

Healthy-SCD1 *

0.0000000

Healthy-SCD2 *

0.0000003

SCD1-SCD2 *

0.0082045

Specificity of the immobilized dRNP-MUT3’ with amplicon sequences
We tested for selectivity of the SCD SNP using the dRNP-MUT3’ complex with
the four amplicons tested previously with dRNP-HTY3’. Each combination of
dRNP-HTY3’ with (900ng Amplicon) was ran at least two times.
I found evidence to support selective binding and detection of dRNP-MUT3’ for
SCD1 amplicon; however, there was no evidence to support selective binding and
detection of dRNP-MUT3’ for SCD1 amplicon. The average responses of the four
amplicon samples (Healthy, SCD1, SCD2, and Scram) were different, with SCD1
amplicon sample with the highest average response at 10.94 and Scram amplicon sample
with the lowest response at 4.75 (One-Way ANOVA: F3, 35 =
 11.38, p = 2.33e-05, Fig. 6).
A post-Tukey test was performed and further supports dRNP-HTY3’ complex’s higher
affinity of binding with SCD1 sample. While the average I-Responses of SCD1 and
SCD2 are similar, there is no statistical significance between average I-Responses
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between SCD2 amplicon and Healthy amplicon (Post-Tukey: p-adj = 0.7444647). The
results are shown in the Table 3 (* notes statistical significance).

Figure 6. The relationship between dRNP-MUT3’ (900ng amplicon type) and average
I-Response (%). Bar heights and bars represent means ± standard deviation. Healthy
(n=9), SCD1 (n=12), SCD2 (n=6), Scram (n=12) (n= number of working transistors).
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Table 3. Post-Tukey analysis of dRNP-MUT3’ sensor responses of amplicon samples
Amplicon Comparison

P-adjusted value

Healthy-SCD1 *

0.0018922

Healthy-SCD2

0.1336568

Healthy-Scram

0.7444647

SCD1-SCD2

0.6687290

SCD1-Scram *

0.0000300

SCD2-Scram *

0.0130985

Conclusion and Future Directions
The use of gFET biosensors has become increasingly popular for detecting large
molecules in biomedical, clinical, and environmental applications (Afsahi et al., 2018;
Forsyth et al., 2017; Justino et al., 2017). The CRISPR-Chip, a gFET biosensor with
immobilized catalytically inactivated CRISPR-Cas9 complex, was able to specifically
detect target DNA sequences with and without the sickle cell disease-associated single
nucleotide polymorphism in both amplicon and genomic samples. The CRISPR-Cas9
complex capturing mechanism is easily modifiable through sgRNA selection since the
sgRNA chosen is target-specific.
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As shown in the Results section, with the dRNP-HTY3’ complex, the
CRISPR-Chip was able to specifically detect the target sequences of healthy patient, with
and without pre-amplification. With the dRNP-MUT3’ complex, the CRISPR-Chip was
able to specifically detect one of the amplified target sequences from a patient with sickle
cell disease. The differences in average current response between the SCD1 and SCD2
samples could be due to patient-to-patient variation. For further testing of this possible
patient variation, future directions would consist of including a third DNA sample of
another patient with sickle cell disease, as well as conducting additional trials to detect a
possible pattern of difference between the patient samples. It is also important to note that
sgRNA-MUT3’ is based off of sgRNA-HTY3’, which has been previously used in
literature. sgRNA-MUT3’ and sgRNA-MUT5’, which were modified to contain the
SCD-associated SNP, may have unexpected off-target effects that could affect its binding
with the target and non-target DNA sequences. The large range in standard deviation of
average current could be attributed to chip-to-chip variability, as well as variation in
enzyme activity due to the length of the assay.
Nonetheless, the collected data shows promising indications for CRISPR-Chip’s
ability to specifically detect and differentiate between DNA samples from a healthy
individual and DNA samples from individuals who have sickle cell disease as there are
obvious and statistically supported differences in average current responses. Future
directions include conducting more data with additional trials as mentioned before, and to
run experiments of the dRNP-MUT3’ complex with genomic samples and of the
dRNP-MUT5’ complex with both amplicon and genomic samples.
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Researched have already demonstrated CRISPR-Chip’s promising diagnostic
potential for genetic diseases with samples containing insertions (BFP) as well as with
samples containing clinically relevant deletions (DMD) (Hajian et al., 2019). As sickle
cell disease can already be diagnosed with a simple blood test at birth, CRISPR-Chip’s
capacity for SCD-associated SNP detection has potential as a gene-editing monitoring
tool for both efficiency and efficacy. Facile detection, analysis, and editing of sickle cell
disease using CRISPR-based editing and monitoring would be beneficial for simple
diagnostic and gene-editing therapeutic treatment of other single nucleotide
polymorphisms as well, such as beta-thalassemia and cystic fibrosis.
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